Why AI Alone Won't Solve Oligonucleotide Discovery
A GEN piece argues that oligonucleotide discovery requires more than AI, highlighting the importance of chemistry, biology, and experimental validation. The argument is a useful counterweight to the notion that better algorithms can replace domain-specific R&D constraints.
The GEN article lands at an important moment because oligonucleotide discovery is one of the areas where AI’s limitations become especially visible. These programs depend on nuanced relationships between sequence, structure, delivery, stability, and biological activity—factors that are difficult to infer from data alone.
That is why the strongest takeaways from the piece are not anti-AI, but anti-overreach. AI can help narrow search space, suggest candidates, and identify patterns across large datasets, yet the actual discovery process still depends on rigorous chemistry and experimental work. In fields like oligonucleotides, where small design changes can have large functional consequences, context matters as much as computation.
The broader implication is that biotech leaders should think of AI as a force multiplier, not a substitute for specialized scientific judgment. The platforms that succeed will be those that integrate model output with human expertise and robust lab validation rather than trying to automate the field wholesale.
This matters commercially as well. Investors often reward AI-native narratives, but therapeutics areas with complex physics and biology may resist simple platformization. The article is a good reminder that not every discovery problem is equally AI-friendly, and the most valuable use of AI may be in guiding decisions rather than generating definitive answers.